Scientists identify broadly neutralizing HIV antibodies by mapping V2 C-strand variability
Updated
Updated · BIOENGINEER.ORG · Apr 29
Scientists identify broadly neutralizing HIV antibodies by mapping V2 C-strand variability
8 articles · Updated · BIOENGINEER.ORG · Apr 29
In vaccinated non-human primates, Q12BBM-069 broadly neutralized strains lacking the Asn130 glycan, while Q7M-675 and serum IgG from animals Q7 and Q8 neutralized the resistant clade B isolate WITO.33.
Researchers linked sensitivity to a V2 C-strand motif spanning residues 164-172, and showed engineered mutations such as I169E/K171E or K168E abolished neutralization, confirming key binding sites.
The Nature study suggests trimer-liposome immunogens can elicit multiple antibody lineages that counter HIV sequence diversity, offering a molecular blueprint for broader, next-generation vaccine design.
This vaccine prevents HIV, but can its insights lead to a cure for the infected?
Can this new vaccine strategy truly outsmart HIV's rapid mutation and escape?
Can artificial intelligence now design the ultimate HIV vaccine that humans could not?
When will this promising HIV vaccine finally begin human trials?
Is a multi-shot V2 apex vaccine better than a single-shot V3 glycan one?
Can this complex vaccine technology be scaled for an affordable global rollout?